Using a two-tier phenotypic screening platform, researchers identified bromocriptine mesylate as a potent and selective inhibitor of chemoresistant prostate cancer cells.
[Translational Oncology]
Home Newsletters Bromocriptine Monotherapy Overcomes Prostate Cancer Chemoresistance in Preclinical Models
